Mounjaro and Sleep Apnoea: What the Evidence Shows

Tirzepatide has been studied in obstructive sleep apnoea (OSA) with obesity in the SURMOUNT-OSA trial, and OSA is a recognised weight-related condition that can make someone eligible for weight-management treatment. In the UK SmPC, Mounjaro's licensed indications are weight management and type 2 diabetes, with OSA appearing as a comorbidity and trial population rather than a separate 'treatment for OSA' indication. So this guide does not claim it as a licensed OSA treatment; discuss OSA with your sleep team.

There has been growing interest in whether weight-loss medicines like Mounjaro can help obstructive sleep apnoea (OSA), a condition closely linked to weight. The honest, UK-based picture is more specific than the headlines: tirzepatide has been studied in OSA with obesity, and OSA is a weight-related condition, but the UK licence frames things carefully.

This guide explains what the SmPC and the SURMOUNT-OSA trial show about Mounjaro and sleep apnoea, why OSA is a weight-related condition, and what the UK licence actually covers. It draws on the UK Summary of Product Characteristics and the NHS. It is general information; OSA itself should be managed with your sleep or clinical team.

Is Mounjaro a treatment for sleep apnoea?

It is worth being precise about the UK position. In the UK SmPC, Mounjaro's licensed indications are weight management and type 2 diabetes, not a standalone 'treatment for obstructive sleep apnoea' ¹. So this guide does not present it as a licensed OSA treatment ¹.

What is true is that OSA is a recognised weight-related comorbidity: the SmPC lists obstructive sleep apnoea among the weight-related conditions, and tirzepatide has been studied specifically in people with OSA and obesity in a trial called SURMOUNT-OSA ¹. So OSA is closely connected to the weight-management picture ¹.

The distinction matters: weight management (for which it is licensed) can be relevant to someone who also has OSA, but that is different from the medicine being a direct, licensed OSA therapy in the UK SmPC ¹. The sections below explain the trial and the connection ¹.

This is exactly the sort of topic where headlines can run ahead of the UK licensing position ¹. Reports of a weight-loss medicine 'treating sleep apnoea' often reflect trial findings or another country's regulatory decision, and it is easy to assume that translates directly into how the medicine is licensed and used here ¹. This guide deliberately stays with what the UK SmPC says, and is clear about where the wider picture is beyond it, so you get an accurate sense of the current UK position ¹.

What SURMOUNT-OSA was

The Mounjaro SmPC refers to SURMOUNT-OSA, a phase 3 study programme that evaluated tirzepatide in adults with obstructive sleep apnoea and obesity¹. So OSA with obesity was specifically the studied population, alongside the main weight-management trials ¹.

The SmPC notes that the adverse-reaction profile in the OSA studies was consistent with that seen in the weight-management trials, so the side-effect picture in this group was not markedly different ¹. The detailed efficacy findings sit in the clinical sections of the SmPC ¹.

This guide does not quote specific OSA outcome figures, because the detailed SURMOUNT-OSA efficacy numbers were not in the SmPC text available here; a clinician or the full SmPC can provide those ¹. The key point is that the medicine has been studied in this group, which underlies the interest in OSA ¹.

Why weight loss matters for OSA

Obstructive sleep apnoea is strongly linked to excess weight, which is why it appears as a weight-related comorbidity in the licensing of weight-loss medicines ¹. Losing weight is a recognised part of managing OSA in people who are overweight, which is the general basis for the interest in weight-loss medicines here ¹.

So for someone who has both obesity and OSA, weight management, which Mounjaro is licensed for, addresses a factor that is relevant to their sleep apnoea ¹. That is the honest, indirect connection: it is licensed for the weight, and the weight is connected to the OSA ¹.

This is different from saying the medicine treats OSA directly as a sleep disorder; OSA itself is diagnosed and managed by sleep services, often with treatments such as CPAP, and that care continues regardless of any weight-loss medicine ². Weight management sits alongside, not instead of, that ¹².

It is genuinely encouraging that there is interest and evidence in this area, since OSA and obesity so often go together and addressing the weight can help ¹². But it is important not to let that encouragement tip into the assumption that a weight-loss medicine is a substitute for OSA treatment ². The two are complementary: managing the weight may improve the OSA picture over time, while the sleep service continues to assess and treat the apnoea itself based on how it actually responds ¹². Treating the two as partners rather than one replacing the other is the safe way to think about it, with the sleep team steering the OSA side ¹².

Considering treatment for weight management? You can start an assessment with a Cloud Pharmacy clinician, who will review your medical history and confirm whether treatment is appropriate.

What the UK licence actually covers

To be clear about scope: in the UK, Mounjaro is licensed for weight management (in defined BMI groups) and type 2 diabetes, and OSA features as a weight-related comorbidity and a studied population, not as a separate licensed indication in the SmPC used here ¹. So eligibility for the medicine still runs through the weight-management or diabetes routes ¹.

Internationally, regulators may take different positions on OSA, but this guide reflects the UK SmPC and does not assert another country's approval as the UK position ¹. Where the picture is broader elsewhere, a clinician can put it in context ¹.

So if you have OSA and obesity, the relevant route is the weight-management one, with your eligibility based on BMI and comorbidities (of which OSA is one), rather than a separate OSA prescription ¹. Our guide on NICE TA1026 covers NHS weight-management eligibility ¹.

Helpfully, the fact that OSA counts as a weight-related comorbidity can be relevant to eligibility itself ¹. Under the weight-management criteria, having a weight-related condition such as OSA is one of the factors that can determine whether someone qualifies, so OSA is part of the picture even though it is not a standalone indication ¹. That is a different thing from being prescribed the medicine 'for OSA', but it does mean your sleep apnoea is relevant information when eligibility for weight management is assessed, so it is worth mentioning ¹².

What this means if you have OSA

If you have OSA and are overweight, the practical implication is that weight management, including with a medicine like Mounjaro if you are eligible, may be relevant to your OSA because of the weight connection, but it does not replace the assessment and management of the sleep apnoea itself ¹². Both should be considered together ¹².

Your sleep or respiratory team manages the OSA, including any CPAP or other treatment, and should be part of the conversation, while weight management is handled through the appropriate route ². Telling each team about the other keeps your care joined up ².

It is also worth not stopping any existing OSA treatment (such as CPAP) on the assumption that a weight-loss medicine will fix it; that is a decision for your sleep team based on reassessment, not an assumption ². Our guide on how Mounjaro works covers the medicine itself ¹.

CPAP and other OSA treatments work regardless of weight, and stopping them prematurely could leave the apnoea untreated, with the daytime sleepiness and other effects that brings ². If weight loss does improve your OSA, your sleep team can reassess and adjust your treatment accordingly, which is the safe way to make any change rather than acting on the scales alone ². So the two run in parallel, with the sleep team steering the OSA side ¹².

What to discuss with your prescriber

If OSA is part of your picture, tell your prescriber and your sleep team, so weight management and OSA care are coordinated ¹². Cover your eligibility for weight-management treatment (where OSA counts as a weight-related comorbidity), and how any weight loss should be reflected in your OSA monitoring ¹.

Be clear that the medicine is being used for weight management (if you are eligible), with OSA as a related condition, rather than as a standalone OSA treatment in the UK licence ¹. Continue your OSA treatment unless your sleep team advises otherwise ².

Our guide on how to choose a weight-loss treatment covers the options. For OSA, the headline is that tirzepatide has been studied in OSA with obesity, OSA is a weight-related condition, and in the UK the relevant route is weight management rather than a separate OSA indication, with your sleep team continuing to manage the apnoea itself and weight management running in parallel rather than one replacing the other, with each team kept informed of the other so your care stays joined up ¹².

Frequently asked questions

Is Mounjaro a treatment for sleep apnoea?

In the UK SmPC, Mounjaro is licensed for weight management and type 2 diabetes, not as a standalone treatment for obstructive sleep apnoea ¹. OSA appears as a weight-related comorbidity and a studied population (SURMOUNT-OSA), so this guide does not claim it as a licensed OSA treatment ¹.

What was the SURMOUNT-OSA trial?

It was a phase 3 study programme evaluating tirzepatide in adults with obstructive sleep apnoea and obesity, referred to in the Mounjaro SmPC ¹. The adverse-reaction profile was consistent with the weight-management trials; this guide does not quote specific OSA outcome figures as they were not in the SmPC text available ¹.

Can losing weight on Mounjaro help my sleep apnoea?

OSA is strongly linked to excess weight, and weight loss is a recognised part of managing OSA in people who are overweight, which is the basis for the interest here ¹. But this is the weight connection, not the medicine treating OSA directly; your sleep team manages the OSA itself ¹².

Can I get Mounjaro on the NHS for sleep apnoea?

In the UK, access runs through the weight-management (or diabetes) route, with OSA counting as one of the weight-related comorbidities, rather than a separate OSA indication ¹. So eligibility is based on BMI and comorbidities under the relevant NICE guidance ¹.

Should I stop my CPAP if I take Mounjaro?

No, not on the assumption that weight loss will fix the OSA. Your OSA, including any CPAP, is managed by your sleep team, and any change should follow their reassessment, not an assumption ². Weight management sits alongside OSA care, not instead of it ¹².

Does the UK licence cover Mounjaro for OSA?

The UK SmPC licenses Mounjaro for weight management and type 2 diabetes, with OSA as a weight-related comorbidity and studied population, not a separate OSA indication ¹. Other countries' regulators may differ, but this guide reflects the UK position and a clinician can put the wider picture in context ¹.

Your next step

Tirzepatide has been studied in obstructive sleep apnoea with obesity in the SURMOUNT-OSA trial, and OSA is a recognised weight-related condition, but in the UK SmPC Mounjaro is licensed for weight management and type 2 diabetes, with OSA appearing as a comorbidity and studied population rather than a separate OSA indication. So this guide does not claim it as a licensed OSA treatment.

If you have OSA and obesity, weight management may be relevant to your OSA through the weight connection, but it does not replace the assessment and care your sleep team provides, including any CPAP. Keep both teams informed, do not stop existing OSA treatment on an assumption, and access weight-management treatment through the appropriate route. OSA does, though, count as a weight-related comorbidity, so it can be relevant when eligibility for weight management is assessed, which is worth mentioning to your prescriber when the two are being considered together. The clearest way to think about it is that improving weight may help the factors that contribute to OSA, while your sleep team continues to manage the OSA itself, so the two strands of care run alongside each other rather than one replacing the other in your overall plan.

Disclaimer

This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.

If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.

If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.

References

1. Mounjaro SmPC 4.1 (licensed indications: weight management and type 2 diabetes; OSA among weight-related comorbidities) and 4.8/5.1 (SURMOUNT-OSA: studied in OSA + obesity; adverse-reaction profile consistent)
2. Tirzepatide (used with diet and exercise; general management; do not stop treatments without advice)